Clinical Impact of Radium-223 on Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

1Yen-Hsiang Chang, 2Hao Lun Luo, 3Li Yu Chen, 3Shiang Ling Lin, 3Ya Ting Huang

1 Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan.
2 Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan.
3 Primo Biotechnology Co., Ltd, Taipei, Taiwan.

This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan.

This systematic review and meta-analysis examined the clinical efficacy of Radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223, the first FDA-approved bone-targeting alpha-emitting radiotherapeutic, has been shown to delay skeletal events, improve quality of life, and prolong overall survival.

The study reported a new metric for progression-free survival (PFS) that analyzes data from multiple studies. While the difference in PFS between Radium-223 monotherapy and the placebo group was not statistically significant, patients who received Radium-223 in combination with treatments such as abiraterone acetate, prednisone, enzalutamide or docetaxel showed a significantly prolonged PFS.

These results underline the therapeutic potential of Radium-223 in combination therapies and provide valuable insights for the optimization of mCRPC treatment strategies.